Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
15 Noviembre 2023 - 3:20PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule
14A Information
Proxy
Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
(Amendment
No. )
Filed
by the Registrant ☒
Filed
by a party other than the Registrant ☐
Check
the appropriate box:
| ☐ | Preliminary
Proxy Statement |
| ☐ | Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ | Definitive
Proxy Statement |
| ☒ | Definitive
Additional Materials |
| ☐ | Soliciting
Material under §240.14a-12 |
DMK
PHARMACEUTICALS CORPORATION |
(Name
of Registrant as Specified In Its Charter) |
|
(Name
of Person(s) Filing Proxy Statement, if other than the Registrant) |
Payment
of Filing Fee (Check all boxes that apply):
| ☐ | Fee
paid previously with preliminary materials |
| ☐ | Fee
computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |
On November 14, 2023,
DMK Pharmaceuticals Corporation commenced mailing a letter to its stockholders in connection with the adjournment of its 2023 Annual
Meeting of Stockholders. A copy of the letter to stockholders follows:
*** YOUR VOTE IS IMPORTANT
***
November 14, 2023
Dear DMK Pharmaceuticals Stockholder:
On November 9, 2023, DMK Pharmaceuticals Corporation
(the “Company”) adjourned its 2023 Annual Meeting of Stockholders to November 30, 2023, at 9:00 a.m. Pacific.
The Annual Meeting will be held virtually on the Internet at:
www.virtualshareholdermeeting.com/DMK2023
A certain number of votes must be received
to constitute a quorum for the transaction of business at the Annual Meeting. To meet this requirement and allow stockholders additional
time to exercise their voting rights, the Company adjourned its Annual Meeting. As a result, you still have an opportunity to vote.
You were a stockholder of the Company as of
the close of business on October 6, 2023. We are sending this reminder notice because, according to records from the vote processor, your
shares are unvoted. Voting is quick and easy. Regardless of the number of shares you own, your vote is important. Whether or
not you plan to attend virtually, please cast your vote as promptly as possible so that your shares will be voted at the adjourned Annual
Meeting.
We urge you to promptly submit your vote by
Internet using the control number located on the enclosed proxy card or by following the instructions that accompanied your voting instruction
form provided by your broker, bank or other nominee.
If you have any questions or need assistance
voting your shares, please contact our proxy solicitor, Saratoga Proxy Consulting, at (888) 368-0379 or (212) 257-1311.
The Company’s proxy materials, along
with its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, are available at www.proxyvote.com.
Thank you for your continued support,
DMK Pharmaceuticals Corporation
DMK Pharmaceuticals (NASDAQ:DMK)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
DMK Pharmaceuticals (NASDAQ:DMK)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024